ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "proteomics"

  • Abstract Number: 0919 • ACR Convergence 2025

    Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns

    Stefanie Kurth1, Andre Tiaden1, Edveena Hanser1, Simone Häner1, Stavros Giaglis1, Florian Geier1, Dominik Burri1, Katarzyna Buczak1, Ute Heider2, Stefan Wild2, Yves Acklin1, Christian Egloff1 and Diego Kyburz3, 1University of Basel, Basel, Switzerland, 2Miltenyi Biotec, Bergisch-Gladbach, Germany, 3University Hospital Basel, Basel, Switzerland

    Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of…
  • Abstract Number: 0070 • ACR Convergence 2025

    Integrating Synovial Protein Signatures and Serum Profiles to Predict Disease Activity and Treatment Response in Early Rheumatoid Arthritis

    Chary López pedrera1, Sagrario Corrales2, Julio Osuna3, Rafaela Ortega-Castro4, Jerusalén Calvo5, Lourdes Ladehesa6, Ismael Sanchez-Pareja2, Laura muñoz-Barrera2, Desiree Ruiz-Vilchez7, Christian Merlo8, MARIA ANGELES AGUIRRE ZAMORANO2, Nuria Barbarroja9, Tomás Cerdó2, Marta Alarcon-Riquelme10, Carlos Pérez Sánchez11, Alejandro Escudero Contreras5 and Concepción Aranda-Valera5, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Spain., Córdoba, Republic of Korea, 4Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 5IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 6IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 7Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 8Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 9Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 10Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 11Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: The analysis of synovial tissue has been instrumental in advancing our understanding of Rheumatoid Arthritis (RA) pathogenesis. As an alternative, the identification of serum…
  • Abstract Number: 2502 • ACR Convergence 2025

    Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study

    Santiago Dans Caballero1, Rafaela Ortega-Castro2, Chary López pedrera3, Alejandro Escudero4, Beatriz Vellón-García5, Carlos Pérez Sánchez6 and Clementina López Medina7, 1Reina Sofia University Hospital, Lebrija, Andalucia, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 4Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain, 5Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 7Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain

    Background/Purpose: Systemic sclerosis (SSc) is a clinically and biologically heterogeneous autoimmune disease characterized by multiorgan involvement, substantial morbidity, and high mortality. Traditional classification systems (based…
  • Abstract Number: 0873 • ACR Convergence 2025

    Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis

    Lihi Eder1, Shangzhong Li2, Philip J. Mease3, Christopher Ritchlin4, Walter P Maksymowych5, Hendrik Schulze-Koops6, Josef Smolen7, Oliver FitzGerald8, Vinod Chandran9, Chun Wu10 and Jinqi Liu2, 1University of Toronto, Toronto, ON, Canada, 2Bristol Myers Squibb, Princeton, NJ, 3Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 4University of Rochester Medical Center, Canandaigua, NY, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, 7Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 8UCD, Dublin 6, Dublin, Ireland, 9Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, 10Bristol Myers Squibb, Princeton

    Background/Purpose: PsA affects male and female patients equally; however, variations in manifestations and treatment response exist between sexes. Deucravacitinib is an oral, selective, allosteric tyrosine…
  • Abstract Number: 0048 • ACR Convergence 2025

    Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting

    Xue Wang1, Fei Wang2, Sílvia Sisó2, Archana Iyer2, Heather Knight2, Lori Duggan2, Yingli Yang2, Liang Jin2, Baoling Cui2, Yupeng He3, Jan Schejbal2, Lucy Phillips2, Bohdan Harvey4 and Yu Tian2, 1AbbVie, South San Francisco, CA, 2AbbVie, Worcester, MA, 3AbbVie, North Chicago, IL, 4AbbVie, Cambridge, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, fibroblast proliferation and progressive joint damage. Understanding the heterogeneity of RA and…
  • Abstract Number: 2402 • ACR Convergence 2025

    High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment

    Alexander Tsoi1, Dionysis Nikolopoulos2, Natalia Sherina3 and Ioannis Parodis1, 1Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 3Karolinska Institutet, Division of Rheumatology, Department of Medicine Solna, and Karolinska University Hospital, Stockholm, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: Belimumab, a BAFF inhibitor, is an effective treatment for systemic lupus erythematosus (SLE), but biomarkers predicting treatment response remain elusive. We aimed to identify…
  • Abstract Number: 0853 • ACR Convergence 2025

    Olink Proteomics Identifies Macrophage Pro-inflammatory Proteins in Maternal Sera Predictive of Fetal Atrioventricular Block Independent of Maternal Health Status

    Philip Carlucci1, Mala Masson2, Colin Phoon3, Ashley Roman3, Peter Izmirly4, Amit Saxena5, Michael Belmont6, Christina Penfield3, Young Mi Lee3, Julie Nusbaum6, Andrew Rubenstein3, Nalani Sachan3, Joel Guthridge7, Judith James7, Elena Sinkovskaya8, Alfred Abuhamad8, Gary Satou9, Whitnee Hogan10, Anita Moon-Grady11, Lisa Howley12, Mary Donofrio13, Stephanie Levasseur14, Miwa Geiger15, Sonal Owens16, Kristopher Cumbermack17, Jyothi Matta18, Gary Joffe19, Christopher Lindblade20, Caitlin Haxel21, Katherine Kohari22, Joshua Copel22, James Strainic23, Tam Doan24, Conisha Holloman24, Stacy Killen25, Theresa Tacy26, Michelle Kaplinski26, Nicola Fraser3, Kelly Ruggles27, Bettina Cuneo28, Jill Buyon3 and Robert Clancy14, 1New York University School of Medicine, New York, NY, 2NYU Langone Medical Center- Division of Rheumatology, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4New York University Grossman School of Medicine, New York, NY, 5Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 6NYU Langone Health, New York, NY, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Eastern Virginia Medical School, Norfolk, VA, 9University of California Los Angeles, Los Angeles, CA, 10University of Utah, Salt Lake City, UT, 11University of California San Francisco, San Francisco, CA, 12Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, 13Children's National Hospital, Washington, DC, 14Columbia University, New York, NY, 15Mount Sinai School of Medicine, New York, NY, 16University of Michigan, Ann Arbo, MI, 17University of Kentucky, Lexington, KY, 18University of Louisville, Louisville, KY, 19Perinatal Associates of New Mexico, Albuquerque, NM, 20Phoenix Children's Hospital, Phoenix, AZ, 21University of Vermont Children's Hospital, Burlington, VT, 22Yale University, New Haven, CT, 23UH Rainbow Babies, Cleveland, OH, 24Baylor College of Medicine, Houston, TX, 25Vanderbilt University, Nashville, TN, 26Stanford University, Stanford, CA, 27NYU Grossman School of Medicine, Brooklyn, NY, 28University of Arizona College of Medicine, Tucson, AZ

    Background/Purpose: Fetal atrioventricular block (fAVB) is presumed dependent on the transplacental passage of SSA/Ro52/60kD autoantibodies that bind to apoptotic fetal cardiomyocytes, triggering macrophage activation and…
  • Abstract Number: 0042 • ACR Convergence 2025

    Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis

    Steven Dang1, Xianwei Li2, Sydney Thib3, Darshini Ganatra4, liqun Diao5, Igor Jurisica6, Vinod Chandran7 and Lihi Eder8, 1Institute of Medical Science, University of Toronto, Toronto, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, 3Women’s College Research Institute, Toronto, Canada, 4Gladman Krembil Psoriatic Arthritis Research Program; Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada, 5Department of Statistics and Actuarial Science, University of Waterloo, Toronto, Canada, 6University Health Network, Toronto, Canada, 7Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, 8University of Toronto, Toronto, ON, Canada

    Background/Purpose: Our recent study characterized immune endotypes in psoriatic arthritis (PsA) patients using mass cytometry of peripheral blood1. We identified an endotype characterized by high…
  • Abstract Number: 2105 • ACR Convergence 2025

    Stratification for elevated urate identifies a pro-inflammatory synovial fluid proteome in knee osteoarthritis: a pilot study

    Tuhina Neogi1, Sayali Dhamne2, Robert Terkeltaub3, Virginia Kraus4, Simon Dillon5 and Towia Libermann5, 1Boston University School of Medicine, Boston, MA, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3Retired, San Diego, CA, 4Duke University, Durham, NC, 5Beth Israel Deaconess Medical Center, Boston, MA

    Background/Purpose: The causes of inflammation, pain fluctuations, and disease progression in osteoarthritis (OA) are not well understood. Soluble urate is a “danger signal”, and synovial…
  • Abstract Number: 0851 • ACR Convergence 2025

    Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis

    CHEN-YU LEE1, Sepehr Taghavi2, Shangzhu Zhang3, Roopa Madhu4, Jasmine Shwetar5, Tyler O'Malley6, Daniel Goldman7, Peter Izmirly8, H Michael Belmont9, Richard Furie10, Noa Schwartz11, Chaim Putterman12, Jennifer Barnas13, Jennifer Anolik14, Sarah French15, Maria Dall'Era16, Judith James17, Joel Guthridge17, Jacob Vasquez18, Mike Nerenberg19, Andrew Concoff20, Christine Schleif21, Kevin Wei22, Thomas Eisenhaure23, Nir Hacohen23, Rachael Bogle24, Johann Gudjonsson25, Lam Tsoi25, Brad Rovin26, Jill Buyon27, Michelle Petri7 and Andrea Fava1, 1Johns Hopkins University, Baltimore, MD, 2Exagen Inc, Escondido, CA, 3Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China (People's Republic), 4Brigham and Women's Hospital, Brookline, MA, 5New York School of Medicine, Ann Arbor, MI, 6Exagen, Vista, CA, 7Johns Hopkins University School of Medicine, Timonium, MD, 8New York University Grossman School of Medicine, New York, NY, 9NYU School of Medicine, New York, NY, 10Division of Rheumatology, Northwell Health, Great Neck, NY, 11Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, 12Albert Einstein College of Medicine, Safed, Israel, 13University of Rochester, Rochester, NY, 14University of Rochester Medical Center, Rochester, NY, 15UCSF, Mill Valley, CA, 16Division of Rheumatology, University of California, San Francisco, CA, 17Oklahoma Medical Research Foundation, Oklahoma City, OK, 18Exagen, Inc., Vista, CA, 19Exagen, DEL MAR, CA, 20Specialty Networks/United Rheumatology, a Cardinal Health Company, N/A, 21Exagen, Carlsbad, CA, 22Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 23Broad Institute, Cambridge, MA, 24University of Michigan, Holland, OH, 25University of Michigan, Ann Arbor, MI, 26The Ohio State University, Columbus, OH, 27NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…
  • Abstract Number: 0037 • ACR Convergence 2025

    A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors

    Natalie McCormick1, Sharan Rai2, Chio Yokose3, Tony Merriman4, Robert Terkeltaub5 and Hyon K. Choi6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital/Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Waltham, MA, 4University of Alabama at Birmingham, Homewood, AL, 5Retired, San Diego, CA, 6MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
  • Abstract Number: 1865 • ACR Convergence 2025

    Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis

    Hanlin Yin1, Wanyi Lin2, Zhangyi zhao1, Chenhan Jia1 and Liangjing Lu1, 1Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China (People's Republic), 2Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China (People's Republic)

    Background/Purpose: Antinuclear antibodies (ANA) are detected in over 95% of systemic sclerosis (SSc) patients. Compared to cutaneous subtype classification, autoantibody-based stratification more accurately predicts survival,…
  • Abstract Number: 0840 • ACR Convergence 2025

    Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases

    Alessandra Ida Celia1, Daksh Saksena2, CHEN-YU LEE3, Carla Guthridge4, Wade DeJager5, Rufei Lu4, Judith James4, Jill Buyon6, Michelle Petri7, Joel Guthridge4, Brad Rovin8 and Andrea Fava3, 1Sapienza University of Rome, Rome, Italy, 2Johns Hopkins University, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, 6NYU Grossman School of Medicine, New York, NY, 7Johns Hopkins University School of Medicine, Timonium, MD, 8The Ohio State University, Columbus, OH

    Background/Purpose: Urine collects the byproducts of kidney biology and has emerged as a valuable, noninvasive source of molecular information that reflects intrarenal pathology. In lupus…
  • Abstract Number: 0026 • ACR Convergence 2025

    Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis

    Bilgesu Safak Tümerdem1, Yi-Nan Li2, Tim Filla3, Rolf Schröder4, Anna Brunn5, Alexandru Micu6, Ayla Nadja Stuetz1, Laura-Marie Lahu6, Aleix Rius Rigau7, Christina Bergmann8, Alexandru-Emil Matei9, Jörg Distler10 and Andrea-Hermina Györfi11, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 2University Hospital of Düsseldorf, Düsseldorf, Germany, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 4Institute of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Institute of Neuropathology, Heinrich-Heine University, University Hospital of Düsseldorf, Düsseldorf, Germany, 6Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, 7Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 8Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 9Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 10University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 11Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany

    Background/Purpose: Immune-mediated inflammatory myopathies (IIMs) are a heterogeneous group of diseases characterized by chronic inflammation, damage and impaired regeneration of the skeletal muscle leading to…
  • Abstract Number: 1856 • ACR Convergence 2025

    Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement

    Ayla Nadja Stuetz1, Giacomo de Luca2, Alexandru-Emil Matei3, Yi-Nan Li4, Veronica Batani2, Tim Filla5, Aleix Rius Rigau6, Bilgesu Safak Tümerdem1, Cosimo Bruni7, Maike Büttner-Herold8, Stefania Rizzo9, Monica De Gaspari9, Markus Eckstein10, Georg Schett11, Cristina Basso9, Jörg Distler12, Marco Matucci-Cerinic13 and Andrea-Hermina Györfi14, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 2Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 4University Hospital of Düsseldorf, Düsseldorf, Germany, 5Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 6Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Department of Nephropathology, University Hospital Erlangen, Erlangen, Germany, 9Cardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University and Hospital of Padua, Padua, Italy, 10Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 11Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 12University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 13University San Raffaele Milano, Milano, Milan, Italy, 14Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany

    Background/Purpose: Primary heart involvement (pHI) is one of the leading causes of death in systemic sclerosis (SSc). However, the cellular and molecular pathomechanisms of SSc-pHI…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology